Bayer's Dual Track: Strong Prostate Data, a Narrow Legal Settlement, and a November Reckoning
Published on 10/26/2026 at 06:41 | Editorial boerse-global.de
Bayer's Saturday release of Phase III data for darolutamid landed alongside a legal development that investors would be forgiven for conflating with the company's long-running cancer litigation. They are not the same thing. The settlement in question concerns allegations of misleading marketing of Roundup — not the separate wave of claims alleging cancer risks. Any read-across from one to the other is misplaced.
What the DASL-HiCaP numbers actually show
In the DASL-HiCaP trial, darolutamid was tested as an add-on to androgen deprivation therapy and radiotherapy in prostate cancer patients at high risk of recurrence. Bayer reported a 58% reduction in the risk of metastases or death versus placebo. The four-year metastasis-free survival rate came in at 95% on darolutamid against 88% on placebo, with a median follow-up of 3.8 years. The data were presented at the ESMO congress.
One caveat belongs in plain sight: no approval has been granted for the use of darolutamid examined in this study. The reported benefit applies to the combined endpoint of metastases or death, and the comparator arm also received androgen deprivation and radiotherapy.
Should investors sell immediately? Or is it worth buying Bayer?
Kidney franchise advances on a second front
Finerenon added its own clinical news. Bayer pointed to previously published subgroup analyses from the Phase III FIND-CKD study showing consistent effects in patients with chronic kidney disease without diabetes — specifically on reductions in UPCR and UACR, and on slowing the loss of kidney function. On 8 October, the US Food and Drug Administration accepted Bayer's marketing application for finerenon in chronic kidney disease without diabetes.
Brussels, red tape, and a 0.1% growth rate
Away from the clinic, Bayer turned its attention to the competitiveness of European agriculture. An Oxford Economics study commissioned by the company, published on 15 October, put average annual growth in EU arable crop production at 0.1% over the 2011–2023 period. Bayer pointed to regulatory obstacles limiting access to seed, crop protection, and digital innovations. Manager Matthias Berninger used the findings on 16 October to call for faster access to innovation and a more innovation-friendly regulatory framework.
The stock and the calendar
Shares slipped 0.3% on Friday to close at €43.92. The next scheduled financial event is 3 November, when Bayer publishes its quarterly statement for the third quarter of 2026 — a release listed for 07:30, accompanied by a media briefing and an investor video conference. Until then, the pipeline headlines and the courtroom headlines will keep running on separate tracks.
Ad
Bayer Stock: New Analysis - 26 October
Fresh Bayer information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
